The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Changing trends in etiology‐based annual mortality from chronic liver disease, from 2007 through 2016
Open accessAbstract
Background & aims Although treatment of hepatitis C virus (HCV) infection has improved, the prevalence of alcoholic liver disease (ALD) has been increasing, so we need an updated estimate of the burden and etiology-specific mortality of chronic liver diseases. We studied trends in age-standardized mortality of chronic liver diseases in adults at least 20 years old in the United States from 2007 through 2016.Methods We collected data from the US Census and National Center for Health Statistics mortality records and identified individuals with HCV infection, ALD, nonalcoholic fatty liver disease, or hepatitis B virus infection using ICD-10 codes. We obtained temporal mortality rate patterns using joinpoint trend analysis with estimates of annual percentage change (APC).Results Age-standardized HCV-related mortality increased from 7.17 per 100,000 persons in 2007 to 8.14 per 100,000 persons in 2013, followed by a marked decrease in the time period at which patients began receiving treatment with direct-acting antiviral agents (from 8.09 per 100,000 persons in 2014 to 7.15 per 100,000 persons in 2016). The APC in HCV mortality increased 2.0%/year from 2007 through 2014 but decreased 6.4%/year from 2014 through 2016. In contrast, age-standardized mortality increased for ALD (APC 2.3% from 2007 through 2013 and APC 5.5% from 2013 through 2016) and nonalcoholic fatty liver disease (APC 6.1% from 2007 through 2013 and APC 11.3% from 2013 through 2016). Mortality related to hepatitis B virus decreased steadily from 2007 through 2016, with an average APC of -2.1% (95% CI -3.0 to -1.2). Etiology-based mortality in minority populations was higher. HCV-related mortality (per 100,000 persons) was highest in non-Hispanic blacks (10.28) and whites (6.92), followed by Hispanics (5.94), and lowest in non-Hispanic Asians (2.33). Non-Hispanic Asians had higher mortality for hepatitis B virus infection (2.82 per 100,000 vs 1.02 for non-Hispanic blacks and 0.47 for non-Hispanic whites).Conclusion In our population-based analysis of chronic liver disease mortality in the United States, the decrease in HCV-related mortality coincided with the introduction of direct-acting antiviral therapies, whereas mortality from ALD and nonalcoholic fatty liver disease increased during the same period. Minorities in the United States have disproportionately higher mortality related to chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, CLD is uniquely associated with complex psychosocial comorbidities, including alcohol use disorder (increasingly among the young population)7, 8 and substance abuse, both of which occur more frequently and at a greater severity among patients with CLD than the general population.9”
From A Behavioral Health Program for Alcohol Use Disorder, Substance Abuse, and Depression in Chronic Liver Disease (2019) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,861
Self-citationvan der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H. H., Dufour, J., Lammert, F., Duarte‐Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,507
Panel, A. I. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,385
Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N. B., Cowie, B., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30579-7 · Cited by 1,350
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y. H., Younossi, Y., Mir, H., & Srishord, M. K. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,072
Davis, G. L., Alter, M. J., El‐Serag, H. B., Poynard, T., & Jennings, L. W. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 879
Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P. N., Landis, C. S., Brown, R. S., Fried, M. W., Terrault, N. A., O’Leary, J. G., Vargas, H. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.010 · Cited by 799
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Self-citation
Cited by
Sorted by citations
Items 201–223 of 223
Samanta, T., Basu, R., Purkait, R., Kar, S., Das, D., & Ganguly, S. (2020) · JGH Open · doi:10.1002/jgh3.12441
Solano-Urrusquieta, A., Álvarez-Licona, N. E., Morales‐González, J. A., Fierros-Oceguera, R., Bastida-Alquicira, J., Ojeda-Yuren, A. S., & Reyes, E. C. (2021) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20210903.16
TREMBLAY, J.-F. (2004) · Chemical & Engineering News · doi:10.1021/cen-v082n017.p014
Nutrition in Patients with Diseases of the Liver and Pancreas
Perri, R. E., & Bouquet, E. (2022) · Nutrition and health · doi:10.1007/978-3-030-82515-7_21
Sargent, S. (2018) · Gastrointestinal Nursing · doi:10.12968/gasn.2018.16.sup10.s6
The Place of Liver Elastography in Diagnosis of Alcohol-Related Liver Disease
Popescu, A., & Foncea, C. G. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105691
Leberfibrose - Diagnostik und innovative Therapieansätze
Roehlen, N., Thimme, R., & Böttler, T. (2022) · Gastro-News · doi:10.1007/s15036-022-3108-8
Obstructive Sleep Apnea: A Gastroenterologist’s Perspective
Köker, İ. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_132-1
Thomas, J. M., & Snih, S. A. (2023) · Annals of Epidemiology · doi:10.1016/j.annepidem.2023.12.004
Agbalajobi, O. M., Ebhohon, E., Amuchi, C. B., Nzugang, E. C., Soladoye, E., Babajide, O., & Adejumo, A. (2024) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03232-6
Cuyàs, B., Alvarado‐Tápias, E., Tan, E. H., Golozar, A., Duarte‐Salles, T., Delmestri, A., Ballbe, J. M. A., Man, W. Y., Burn, E., Guarner, C., et al. (2024) · medRxiv · doi:10.1101/2024.08.05.24311466
Pulmonary complications in liver cirrhosis
Thévenot, T., Raevens, S., Aujayeb, A., Cadranel, J., Banini, B. A., & DuBrock, H. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00014-x
Prevalence of liver disease around the world
Cortez‐Pinto, H., Craciun, A., Crespo, R. R., & Carvalhana, S. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00001-0
The Economics of Liver Fibrosis Diagnosis: Systematic Review of Non‐Invasive Test Cost‐Effectiveness
Cardoso, M. M. D. A., Romeiro, F. G., dos Santos, W. M., Rúgolo, J. R. M., de Almeida, J. T. C., Thabane, L., Thavorn, K., & Tarride, J. (2025) · Liver international communications. · doi:10.1002/lci2.70030
Yoo, J.-J., Lee, D. H., Chang, Y., Jo, H., Cho, Y. Y., Lee, S., Kim, L. Y., & Jang, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26241147
Faizan, A., Ahmad, F., Fatima, E., Tariq, Z., Rehman, F. K. U., & Nashwan, A. J. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01893-9
Rehman, K. A., Javaid, S. S., Pirih, F., Malik, M., Tirmizi, S. U., Amin, E., Faizan, A., Bilal, Z., Khatoon, A., Afzal, E., et al. (2026) · Medicine · doi:10.1097/md.0000000000048363
Tariq, M. A., Malik, M. K., Malik, A. F., Khan, M., Majoka, Z. A., Malik, M. S., & Amin, H. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.06.010
Self-citationZheng, J., Song, Y., 徐, 浩., Feng, B., & 谢艳迪 (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1861502
Sarlin, S. K., Lim, H., Li, X., Liu, Y., & Thrift, A. P. (2026) · Cancer Causes & Control · doi:10.1007/s10552-026-02238-w
Espinosa, E. B., Gonzalez, Y. M., Patterson, L., Mendoza, J. A., del Campo, W. L., Sanchez, G., Castro, F. S., Dominguez, Y., Rivera, J. T. V., Perez, A. J. R., et al. (2026) · Cureus · doi:10.7759/cureus.116773
Metadata
- Authors
- Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A.
- Affiliations
- Stanford Medicine (US)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Kim, Donghee
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 155
- Issue
- 4
- Pages
- 1154-1163.e3
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC6467699
- OpenAlex
- W2884426912
- Cited by
- 223
- References
- 38
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 21 · 2023: 23 · 2022: 30 · 2021: 34 · 2020: 40 · 2019: 36 · 2018: 5
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007056)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- chronic liver disease, hepatitis C virus, alcoholic liver disease, non-alcoholic fatty liver disease, hepatitis B virus, mortality trends, direct-acting antivirals, age-standardized mortality rates, racial and ethnic disparities, minority groups, mortality burden, annual percent change, ICD-10
- MeSH terms
- Adult, Antiviral Agents, Asian, Black or African American, Cause of Death, Female, Hispanic or Latino, Humans, Liver Diseases, Alcoholic, Male, Middle Aged, Risk Factors, Time Factors, United States, Prevalence, Age Distribution, Censuses, Hepatitis B, Chronic, Hepatitis C, Chronic, White People, Health Status Disparities, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
